Elypta

Elypta (Elypta AB) is a Solna-based biotech company developing a metabolism-based liquid biopsy, the MIRAM Kit, for early cancer detection. It measures the GAGome, a set of systemic biomarkers of tumor metabolism in urine, and applies machine learning to noninvasively detect cancer signatures. Elypta is a main partner in the EU-funded PREDI-LYNCH project, a pan-European hereditary multi-cancer screening initiative for people with Lynch Syndrome that received EUR 13.6 million in EU funding, and it has completed the largest kidney cancer recurrence monitoring study using its urine test. The company holds ISO 13485:2016 certification.